Cannabis scientists at Johns Hopkins University have been working for years to develop a new cannabis strain for the treatment of multiple sclerosis, which has been devastating millions of Americans since the drug was first introduced in the U.S. in 1996.
The researchers developed a strain that is not only safe, but that is also much more potent than other strains currently available in the United States.
The team has already successfully tested its strain on mice.
Now they are working to get it into the hands of the millions of patients suffering from MS.
The cannabis strain developed by Johns Hopkins researchers is the first one to be able to treat multiple sclerosis in a safe and effective way.
It’s also the first cannabis strain to be used on humans in a controlled trial in the treatment phase.
“It’s a big step,” said Dr. Steven Schonberg, one of the Johns Hopkins research scientists who developed the strain.
“We have shown in the mice that it’s safe and is a great candidate for humans.
It is also a very potent strain.”
The Johns Hopkins team is also working to develop an alternative strain that has also been shown to be safe and has been approved for use by the Food and Drug Administration.
That strain is called Blue Diamond, and it has been developed by researchers at the University of Washington.
Schonberg said that the Johnskins team is focused on developing Blue Diamond for people with MS who are currently not able to receive other forms of medical cannabis.
“If we can do this in a reasonable timeframe, and if we can get the approvals for people who have the symptoms of MS, we can help them take their medicine and get back to work,” he said.
For years, researchers have been using different types of cannabis for different kinds of diseases, but no one has been able to produce a strain with both high and low THC levels that is both safe and potent.
Schonberger said that researchers are working toward a cannabis strain that can be used for people at low or high risk for MS.
“People who are not suffering from the disease and have a high tolerance for THC, for example, or a high dose of THC can be able and potentially safely use cannabis in a relatively safe and safe way,” he explained.
“This is going to be a really important tool for us to help people who are suffering and for people to have access to medicine.”
Schonberger and his team are currently developing Blue Dose, which is a new strain of cannabis that has been found to have similar effects as THC in mice.
The Blue Doses strain is not yet FDA-approved for humans, but the Johnsens are hoping to get the approval within the next few months.
In addition to Blue Dosed, the Johnses team has developed a marijuana strain that contains CBD, a compound that is found in many strains of marijuana.
The strain is also the only strain to have been successfully tested in humans in clinical trials.
“We are hoping that this will be a good first step in the development of a new marijuana strain for MS,” Schoneng said.